RecruitingPhase 3NCT05084196

Melatonin for Prevention of Kidney Injury

Melatonin for the Prevention of Antibiotic Associated Acute Kidney Injury

Sponsor

Rutgers, The State University of New Jersey

Enrollment

300 participants

Start Date

Jun 5, 2023

Study Type

INTERVENTIONAL

Conditions

Acute Kidney Injury Adverse Drug Event

Summary

This study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Melatonin and Placebo Capsule for people with acute kidney injury and adverse drug event. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMelatonin

Melatonin 5 mg capsule by mouth at bedtime

OTHERPlacebo Capsule

Placebo capsule by mouth at bedtime

Locations(2)

Robert Wood Johnson University Hospital

New Brunswick, New Jersey, United States

Robert Wood Johnson University Hospital Somerset

Somerville, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05084196

Related Trials

Fluid-removal Guided by VeXUS Score With Usual Care in Patients With Acute Kidney Injury After Cardiac Surgery

NCT062517132 locations

Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy

NCT072125951 location

FST Analysis Supporting Timely Therapy and Risk Assessment Via Clinical Decision Support for Kids

NCT077184641 location

Effect of a Furosemide Stress Test-Guided Strategy on Liberation From Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury

NCT062299901 location

Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury

NCT069547406 locations